Heart Failure (HFpEF): GLP-1 Treatment for Obesity-Related HFpEF
Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure in people with obesity. The STEP-HFpEF trial demonstrated that semaglutide produces significant improvements in symptoms, exercise capacity, and weight in this population.
Why Obesity Causes HFpEF and How GLP-1 Treatment Changes the Prognosis
HFpEF is characterized by a stiffened left ventricle that fills poorly despite a preserved ejection fraction. In people with obesity, excess pericardial fat directly compresses the heart, visceral adiposity increases cardiac filling pressures, and chronic inflammation drives myocardial fibrosis. The clinical picture is one of exercise intolerance, leg swelling, shortness of breath with exertion, and reduced quality of life that often begins long before any heart failure diagnosis is considered.
The STEP-HFpEF trial published in 2023 demonstrated that semaglutide produced significant reductions in heart failure symptom scores, meaningful improvements in 6-minute walk distance, and substantial weight loss compared to placebo in patients with obesity and HFpEF. This trial established GLP-1 therapy as an evidence-based treatment for obesity-related HFpEF, a condition that previously had limited specific therapeutic options.
Beyond symptom and weight outcomes, GLP-1 therapy addresses the underlying mechanisms that drive HFpEF in obesity: reducing pericardial and visceral fat, lowering cardiac filling pressures, decreasing inflammation, and improving cardiometabolic risk factors that worsen heart failure progression. The SELECT trial reinforced these cardiovascular benefits in the broader obesity population.
A genuine therapeutic advance: STEP-HFpEF was the first trial to show meaningful symptom and functional benefit specifically in obesity-related HFpEF. Standard heart failure medications (diuretics, ACE inhibitors, ARBs, beta-blockers) treat symptoms but do not address the underlying mechanism. Our medical team builds a treatment plan that combines GLP-1 therapy with appropriate heart failure care.
How Tactus Health Evaluates HFpEF
The evaluation begins with a structured clinical history that documents heart failure symptoms, exercise tolerance, current cardiovascular medications, prior echocardiograms, and any hospitalizations. Our licensed providers coordinate with cardiology when ongoing heart failure management is in place.
Lab work covers BNP or NT-proBNP, fasting glucose, hemoglobin A1c, comprehensive metabolic panel (including renal function), lipid panel, TSH, free T4, and a CBC. When labs and clinical picture support GLP-1 therapy, our medical team builds a plan that integrates with existing cardiac care. Treatment is monitored with follow-up labs and structured symptom and functional tracking.
Common Questions About HFpEF
Heart failure with reduced ejection fraction (HFrEF) involves a weakened heart that cannot pump effectively. HFpEF involves a stiff heart that fills poorly even though its pumping function is preserved. HFpEF is more common in older adults, women, and people with obesity, hypertension, or diabetes. The treatments differ because the underlying mechanism differs.
In the STEP-HFpEF trials, semaglutide was used alongside standard heart failure medications including diuretics, ACE inhibitors, ARBs, and beta-blockers without significant safety signals. As with any new medication, our medical team coordinates with cardiology when patients are on multiple heart failure therapies.
The STEP-HFpEF trial showed meaningful improvements in symptom scores and exercise capacity over 52 weeks, with benefits appearing progressively as weight loss and metabolic improvement accumulated. Some symptom improvement is reported within the first few months of treatment.
Treat the HFpEF. Reduce the Burden.
Free consultation with our medical team. In-person at Sugar Hill or by telehealth. Labs ordered same day.
